Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

This achievement further emphasises the drug’s efficacy across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard. The use of Dupixent in AD has ...

This combination study is designed to evaluate the safety, PK, PD and efficacy against DUPIXENT in patients with moderate-to-severe AD, with readout expected in the second half of 2026.

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Filippos Maniatis, Healthcare Analyst at GlobalData, remarks, "With Dupixent setting the gold standard for AD, Sanofi has raised the bar for competitors in this space. However, Sanofi’s CEO has ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

“Having Dupixent as the gold standard for AD, Sanofi has set a high benchmark for competitors within the space. Nevertheless, Sanofi’s CEO has underscored the need for increased ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

Dupixent (dupilumab) is tipped to be the market ... strong performance in clinical trials improving atopic dermatitis (AD) in moderate-to-severe patients, where it is the first systemic drug ...